The global blood cancer therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The chronic myeloid leukemia (CML) segment is expected to account for the largest share of the global blood cancer therapeutics market in terms of revenue, followed by acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). The North American region is expected to account for the largest share of the global blood cancer therapeutics market in terms of revenue, followed by Europe and Asia Pacific.
-The global market for blood cancer therapeutics is expected to grow at a CAGR of 5.2% from 2016 to 2020. -Blood cancer therapeutics are used in the treatment of leukemia, lymphoma, and myeloma.
-Blood cancer therapeutics are used in the treatment of leukemia, lymphoma, and myeloma. -In 2015, the US accounted for about 50% of the total revenue generated by blood cancer therapeutics globally with an estimated value of $6 billion USD.
Industry Growth Insights published a new data on “Blood Cancer Therapeutics Market”. The research report is titled “Blood Cancer Therapeutics Market research by Types (Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML)), By Applications (Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics), By Players/Companies AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Novartis, Boehringer Ingelheim, Pfizer, Sanofi”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood Cancer Therapeutics Market Research Report
By Type
Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML)
By Application
Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics
By Companies
AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Novartis, Boehringer Ingelheim, Pfizer, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Blood Cancer Therapeutics Market Report Segments:
The global Blood Cancer Therapeutics market is segmented on the basis of:
Types
Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Roche
- Novartis
- Boehringer Ingelheim
- Pfizer
- Sanofi
Highlights of The Blood Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chronic Myeloid Leukemia (CML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- By Application:
- Cancer Research Centers
- Cancer Hospital
- Surgical Centers
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Blood cancer therapeutics is a field of medicine that focuses on the use of drugs and other treatments to treat blood cancers.
Some of the key players operating in the blood cancer therapeutics market are AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Novartis, Boehringer Ingelheim, Pfizer, Sanofi.
The blood cancer therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Blood Cancer Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Blood Cancer Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Blood Cancer Therapeutics Market - Supply Chain
4.5. Global Blood Cancer Therapeutics Market Forecast
4.5.1. Blood Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Blood Cancer Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Blood Cancer Therapeutics Market Absolute $ Opportunity
5. Global Blood Cancer Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Blood Cancer Therapeutics Market Size and Volume Forecast by Type
5.3.1. Chronic Myeloid Leukemia (CML)
5.3.2. Acute Lymphocytic Leukemia (ALL)
5.3.3. Chronic Lymphocytic Leukemia (CLL)
5.3.4. Acute Myeloid Leukemia (AML)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Blood Cancer Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Blood Cancer Therapeutics Market Size and Volume Forecast by Application
6.3.1. Cancer Research Centers
6.3.2. Cancer Hospital
6.3.3. Surgical Centers
6.3.4. Clinics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Blood Cancer Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Blood Cancer Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Blood Cancer Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Blood Cancer Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Blood Cancer Therapeutics Demand Share Forecast, 2019-2029
9. North America Blood Cancer Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Blood Cancer Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Blood Cancer Therapeutics Market Size and Volume Forecast by Application
9.4.1. Cancer Research Centers
9.4.2. Cancer Hospital
9.4.3. Surgical Centers
9.4.4. Clinics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Blood Cancer Therapeutics Market Size and Volume Forecast by Type
9.7.1. Chronic Myeloid Leukemia (CML)
9.7.2. Acute Lymphocytic Leukemia (ALL)
9.7.3. Chronic Lymphocytic Leukemia (CLL)
9.7.4. Acute Myeloid Leukemia (AML)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Blood Cancer Therapeutics Demand Share Forecast, 2019-2029
10. Latin America Blood Cancer Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Blood Cancer Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Blood Cancer Therapeutics Market Size and Volume Forecast by Application
10.4.1. Cancer Research Centers
10.4.2. Cancer Hospital
10.4.3. Surgical Centers
10.4.4. Clinics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Blood Cancer Therapeutics Market Size and Volume Forecast by Type
10.7.1. Chronic Myeloid Leukemia (CML)
10.7.2. Acute Lymphocytic Leukemia (ALL)
10.7.3. Chronic Lymphocytic Leukemia (CLL)
10.7.4. Acute Myeloid Leukemia (AML)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Blood Cancer Therapeutics Demand Share Forecast, 2019-2029
11. Europe Blood Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Blood Cancer Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Blood Cancer Therapeutics Market Size and Volume Forecast by Application
11.4.1. Cancer Research Centers
11.4.2. Cancer Hospital
11.4.3. Surgical Centers
11.4.4. Clinics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Blood Cancer Therapeutics Market Size and Volume Forecast by Type
11.7.1. Chronic Myeloid Leukemia (CML)
11.7.2. Acute LymphocyticLeukemia (ALL)
11.7.3. Chronic Lymphocytic Leukemia (CLL)
11.7.4. Acute Myeloid Leukemia (AML)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Blood Cancer Therapeutics Demand Share, 2019-2029
12. Asia Pacific Blood Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Blood Cancer Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Blood Cancer Therapeutics Market Size and Volume Forecast by Application
12.4.1. Cancer Research Centers
12.4.2. Cancer Hospital
12.4.3. Surgical Centers
12.4.4. Clinics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Blood Cancer Therapeutics Market Size and Volume Forecast by Type
12.7.1. Chronic Myeloid Leukemia (CML)
12.7.2. Acute Lymphocytic Leukemia (ALL)
12.7.3. Chronic Lymphocytic Leukemia (CLL)
12.7.4. Acute Myeloid Leukemia (AML)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Blood Cancer Therapeutics Demand Share, 2019-2029
13. Middle East & Africa Blood Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Blood Cancer Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Blood Cancer Therapeutics Market Size and Volume Forecast by Application
13.4.1. Cancer Research Centers
13.4.2. Cancer Hospital
13.4.3. Surgical Centers
13.4.4. Clinics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Blood Cancer Therapeutics Market Size and Volume Forecast by Type
13.7.1. Chronic Myeloid Leukemia (CML)
13.7.2. Acute Lymphocytic Leukemia (ALL)
13.7.3. Chronic Lymphocytic Leukemia (CLL)
13.7.4. Acute Myeloid Leukemia (AML)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Blood Cancer Therapeutics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Blood Cancer Therapeutics Market: Market Share Analysis
14.2. Blood Cancer Therapeutics Distributors and Customers
14.3. Blood Cancer Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Boehringer Ingelheim
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sanofi
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
